ACUMEN PHARMACEUTICALS INC
ABOSNASDAQ🏆 #3688 by market capEarnings Mar 24 · PostUS Equity
$2.38▲ $0.10 (+4.39%)
Market closed · at closeTrack ABOS
Get earnings, price moves & breaking news on Telegram
24h▲ 4.4%
7d▲ 15.5%
14d▲ 43.4%
30d▲ 6.5%
ytd▲ 14.1%
1y▲ 5.3%
🏦Market Cap
$172M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
113.5x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $2.30 – $2.49
- 52-Week Range
- $1.50 – $3.60
- Volume (shares)
- 129,286
- Avg Volume (shares)
- —
- Shares Outstanding
- 72.3M
- Next Earnings
- 2027-03-24
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 113.5x
- EPS (TTM)
- $-1.63
- Dividend Yield
- —
- Dilution (1yr)
- +0.9%
ACUMEN PHARMACEUTICALS INC
ABOSFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$124M▲ +8.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$116M▲ +34.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
60.6M▲ +0.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$23M▲ +$17M YoY
StockOtter · stockotter.spaceAbout ACUMEN PHARMACEUTICALS INC
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
12 analysts
Strong Buy6
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.